Back to News
Market Impact: 0.35
Full-Life Technologies Reports Encouraging Preliminary Phase 1 Safety and PSA Decline for FL-020 in mCRPC at ESMO 2026
Source: PR Newswire
Healthcare & Biotech
Phase 1 dose-escalation data for an investigational lutetium-177 therapy in patients with mCRPC showed no dose-limiting toxicities; xerostomia was predominantly Grade 1, with no Grade 3 cases. All lutetium-177-naive patients achieved PSA50, though the article fragment does not provide the sample size or further details on the additional 88.9% figure.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
More News
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- Investing.com’s stocks of the week
- Jefferies raises Zymeworks stock price target on Roche deal
- Cumberland Pharmaceuticals stock tumbles on trial results